Get the Stockscreener App
59.76
0.69%
0.41
After Hours:
59.80
0.04
+0.07%
Disc Medicine Inc stock is traded at $59.76, with a volume of 336.07K.
It is up +0.69% in the last 24 hours and up +12.84% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$59.35
Open:
$59.27
24h Volume:
336.07K
Relative Volume:
0.90
Market Cap:
$2.07B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-16.28
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
-1.35%
1M Performance:
+12.84%
6M Performance:
+7.10%
1Y Performance:
+38.46%
1-Day Range:
$58.86
$60.80
1-Week Range:
$58.63
$61.59
52-Week Range:
$30.82
$68.73
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
59.76 | 2.06B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Is Disc Medicine Inc. stock overvalued or undervaluedEarnings Report Recommendation To Watch Now - jammulinksnews.com
Institutional Investors in Disc Medicine, Inc. (NASDAQ:IRON) See US$140m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
Why Disc Medicine Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - metal.it
Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT - MSN
How many analysts rate Disc Medicine Inc. as a “Buy”Tremendous wealth creation - jammulinksnews.com
Disc Medicine's NDA Submission for Bitopertin in EPP: A High-Probability Catalyst for Value Creation - AInvest
Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 - Insider Monkey
What is the dividend policy of Disc Medicine Inc. stockMaximize gains with strategic stock entries - jammulinksnews.com
Is Disc Medicine Inc. a growth stock or a value stockGet daily expert analysis for smarter investing - jammulinksnews.com
Are Investors Undervaluing Disc Medicine, Inc. (NASDAQ:IRON) By 49%? - Yahoo Finance
How does Disc Medicine Inc. compare to its industry peersExpert Picks Watchlist For 2025 - jammulinksnews.com
How volatile is Disc Medicine Inc. stock compared to the marketBreakneck growth rates - jammulinksnews.com
What are analysts’ price targets for Disc Medicine Inc. in the next 12 monthsGet ahead with breakthrough trading ideas - jammulinksnews.com
Published on: 2025-07-28 05:56:42 - jammulinksnews.com
Should I hold or sell Disc Medicine Inc. stock in 2025Invest smarter with real-time trading signals - jammulinksnews.com
When is the best time to buy Disc Medicine Inc. stockWatchlist Winner Update - metal.it
How strong is Disc Medicine Inc. company’s balance sheetBuild wealth faster with expert stock picks - jammulinksnews.com
Is Disc Medicine Inc. stock a growth or value play2x Return Forecast - metal.it
Insider Selling at Disc Medicine Inc.: A Balancing Act Between Portfolio Strategy and Investor Sentiment - AInvest
Is Disc Medicine Inc. a good long term investmentFree Stock Movement Tracking - PrintWeekIndia
Can Disc Medicine Inc. stock recover from recent declineSuperior profit margins - jammulinksnews.com
What drives Disc Medicine Inc. stock priceBreakthrough capital growth - PrintWeekIndia
10 Best Mid Cap Stocks to Buy According to Billionaires - Insider Monkey
Is Disc Medicine Inc. stock overhyped or has real potentialBreakthrough wealth creation - jammulinksnews.com
Disc Medicine Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - Autocar Professional
What analysts say about Disc Medicine Inc. stockUnrivaled growth potential - Autocar Professional
Disc Medicine’s Strategic Advancements and Regulatory Progress Drive Buy Rating - TipRanks
Disc Medicine To Seek FDA Approval For Bitopertin In EPP, A Painful Sunlight Sensitivity Disorder - Nasdaq
Disc Medicine’s (IRON) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Disc Medicine's NDA Submission for Bitopertin in EPP: A Catalyst-Driven Opportunity in a High-Unmet-Need Market - AInvest
Disc Medicine to submit NDA for bitopertin in EPP in October By Investing.com - Investing.com India
Truist Securities initiates Disc Medicine stock with Buy rating, $86 target - Investing.com Canada
Disc Medicine to submit NDA for bitopertin in EPP in October - Investing.com
Disc Medicine, Inc. Receives Positive FDA Feedback for Bitopertin NDA Submission in Erythropoietic Protoporphyria - Nasdaq
Disc Medicine Announces Positive Pre-NDA Meeting and - GlobeNewswire
Breakthrough EPP Treatment Advances: FDA Green-Lights Bitopertin NDA Filing for Rare Blood Disease - Stock Titan
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):